UroGen Pharma Ltd. Inventory Write-down
UroGen Pharma Ltd. (URGN) reported Inventory Write-down of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2024-03-14
- UroGen Pharma Ltd. inventory write-down for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. inventory write-down for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. inventory write-down for the quarter ending 2022-12-31 was $255.00K.
- UroGen Pharma Ltd. inventory write-down for the quarter ending 2022-09-30 was $350.00K.
- UroGen Pharma Ltd. inventory write-down for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- UroGen Pharma Ltd. inventory write-down for fiscal 2022 was $870.00K.
- UroGen Pharma Ltd. inventory write-down for fiscal 2021 was $0.00.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | $255.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $605.00K derived: sum of 2 quarters · filed 2024-03-14 | $870.00K 10-K · filed 2024-03-14 | |
| 2022-09-30 | $350.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $615.00K 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $265.00K 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $0.00 derived: sum of 2 quarters · filed 2023-03-24 | $0.00 10-K · filed 2023-03-24 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |